Nanosuspensions as a promising approach to enhance bioavailability of poorly soluble drugs : An update
Solubility is a vital factor for devloping drug delivery systems for poorly water soluble drugs. Several conventional approaches for enhancement of solubility have limited applicability, especially when the drugs are poorly water soluble. Nanosuspension technology can be used to enhance the solubilty, stability as well as the bioavailability of poorly water soluble drugs. Nanosuspensions are biphasic systems comperising of pure drug particles dispersed in an aqueous vehicle, stabilized by surfac active agents. Fabrication of nanosuspension is simple and more advantageous than other approaches. Techniques like high-pressure homogenization, wet milling, emulsification, solvent evaporation, bottom up technology and top down technology have been applicable in the fabrication of nanosuspensions. Nanosuspension delivery is possible by several routes, such as oral, pulmonary, parenteral and ocular routes. Nanosuspension not only solves solubility and bioavailability issue, but improve drug safety and efficacy. In this context, we reviewed the current techniques used to develop nanosuspensions and their recents studies application in drug delivery system.
Keywords : Solubility, fabrication, Characterization, Applications, Nanosuspension.
2. Rupali L, Shid, Shashikant, N, Dhole, Nilesh Kulkarni, Santosh L, Shid, Nanosuspension : A Review, Int. J. Pharm. Sci. Rev. Res, 2013; 22(1):98-106.
3. Wang L, Du J, Zhou Y, Wang Y, Safety of nanosuspensions in drug delivery. Nanomedicine : Nanotechnology, Biology and Medicine, 2017; 13(2):455-469.
4. Liversidge GG, Cundy KC, Particle size reduction for improvement of oral bioavailability of hydrophobic drugs, Absolute oral bioavailability of nanocrystalline danazol in beagle dogs, International journal of pharmaceutics, 1995; 125(1):91-7.
5. Pu X, Sun J, Li M, He Z, Formulation of nanosuspensions as a new approach for the delivery of poorly soluble drugs, Current nanoscience, 2009; 5(4):417-427.
6. Mohanty S, Boga P, Role of Nanoparticles in Drug Delivery System. International Journal of Research in Pharmaceutical and Biomedical Sciences, 2010; 1(2):41-66.
7. Nagare SK, GHUGHURE S, SALUNKE S, Jadhav SG, DHORE R, A review on Nanosuspensionan innovative acceptable approach in novel delivery system, Uni. J. Pharm, 2012; 1(1):19-31.
8. Chandra A, Sharma U, Jain SK, Soni RK, Nanosuspension an overview, Journal of Drug Delivery and Therapeutics,2013;3(6):162-7.
9. Pandey S, Devmurari V, Goyani M, Ashapuri H, Nanosuspension, Formulation, characterization and evaluation, International Journal of Pharma and Bio Sciences, 2010; 1(2): 1-10.
10. Langguth P, Hanafy A, Frenzel D, Grenier P, Nhamias A, Ohlig T, Vergnault G, Spahn Langguth H, Nanosuspension formulations for low-soluble drugs,pharmacokinetic evaluation using spironolactone as model compound, Drug development and industrial pharmacy,2005;31(3):319-329.
11. Gao L, Zhang D, Chen M, Drug nanocrystals for the formulation of poorly soluble drugs and its application as a potential drug delivery system, Journal of Nanoparticle Research; 2008; 845-862.
12. Muller RH, Jacobs C, Kayer O, Nanosuspensions for the formulation of poorly soluble drugs, Pharmaceutical emulsion and suspension, New York, Marcel Dekker; 2000. P. 383- 407.
13. Reddy GA, Anilchowdary Y, Nanosuspension technology, a review, IJPI’s Journal of Pharmaceutics and Cosmetology, 2012; 2(8):47-52.
14. Keck CM, Muller RH, Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation, European journal of pharmaceutics and biopharmaceutics, 2006; 62(1):3-16.
15. Mane AN, Gilda SS, Ghadge AA, Bhosekar NR, Bhosale RR, Nanosuspension A Novel Carrier For Lipidic Drug Transfer, Scholars Academic Journal of Pharmacy (SAJP) ISSN, 2014 ; 3(1):2320-4206.
16. Barker R, Parmar A, Kirkeby M, Bjorklund A, Thompson A, Brundin P, Are stem cell-based therapies for Parkinson’s disease ready for the clinic in Journal of Parkinson's disease, 2016; 6(1): 57-63.
17. Bhowmik D, Harish G, Duraivel S, Kumar BP, Raghuvanshi V, Kumar KS. Nanosuspension-A novel approaches in drug delivery system. The Pharma Innovation. 2013; 1(12):50.
18. Yadav M, Dhole S, Chavan P, Nanosuspension, a novel techniques in drug delivery system, World Journal of Pharmacy and Pharmaceutical Sciences, 2014; 3(2):410-433.
19. De PK, Chakraborty S, Das S, Nanosuspensions, Potent vehicles for drug delivery and bioavailability enhancement of lipophilic drugs, Journal of Pharmacy Research, 2012; 5(3):48-54.
20. Gaddam PK, Balkundhi S, Cherukuri S, Chappidi SRA, Review on Nanosuspension technology in drug delivery system, Journal of Comprehensive Pharmacy, Copyriths 2014-2015 GCP online.
21. Kavitha VB, Neethu CS, Dineshkumar B, Krishnakumar K, John A, Nanosuspension formulation, An improved drug delivery system, Nanosci Nanotechnol Int J, 2014; (4):1-5.
22. Bosselmann S, Williams RO, Route-specific challenges in the delivery of poorly watersoluble drugs, InFormulating poorly water soluble drugs, New York, NY; 2012; 1-26.
23. Patravale VB, Kulkarni RM, Nanosuspensions, a promising drug delivery strategy, Journal of pharmacy and pharmacology, 2004; 56(7):827-840.
24. Mhatre R, Chinchole U, Desai, Chavan R, Review nanosuspensions,International Journal of Pharmaceutical Sciences Review and Research, 2012; 13(1): 118–124.
25. Teeranachaideekul V, Junyaprasert VB, Souto EB, Müller RH, Development of ascorbyl palmitate nanocrystals applying the nanosuspension technology, International journal of pharmaceutics, 2008; 354(1-2):227-234.
26. Gaumet M, Vargas A, Gurny R, Delie F, Nanoparticles for drug delivery the need for precision in reporting particle size parameters, European journal of pharmaceutics and biopharmaceutics, 2008; 69(1):1-9.
27. Chingunpitak J, Puttipipatkhachorn S, Chavalitshewinkoon-Petmitr P, Tozuka Y, Moribe K, Yamamoto K, Formation, physical stability and in vitro antimalarial activity of dihydroartemisinin nanosuspensions obtained by co-grinding method, Drug development and industrial pharmacy, 2008; 34(3):314-322.
28. Lindfors L, Skantze P, Skantze U, Westergren J, Olsson U, Amorphous drug nanosuspensions. 3. Particle dissolution and crystal growth. Langmuir, 2007 ; 23(19) :9866-9874.
29. Filipe V, Hawe A, Jiskoot W, Critical evaluation of Nanoparticle Tracking Analysis (NTA) by NanoSight for the measurement of nanoparticles and protein aggregates, Pharmaceutical research, 2010; 27(5):796-810.
30. Thang NM, Geckeis H, Kim JI, Beck HP, Application of the flow field flow fractionation (FFFF) to the characterization of aquatic humic colloids, evaluation and optimization of the method, Colloids and Surfaces A Physicochemical and Engineering Aspects, 2001; 181(1-3):289-301.
31. Fakes MG, Vakkalagadda BJ, Qian F, Desikan S, Gandhi RB, Lai C, Hsieh A, Franchini MK, Toale H, Brown J, Enhancement of oral bioavailability of an HIV-attachment inhibitor by nanosizing and amorphous formulation approaches, International journal of pharmaceutics, 2009; 370(1-2):167-74.
32. Kawakami K, Modification of physicochemical characteristics of active pharmaceutical ingredients and application of supersaturatable dosage forms for improving bioavailability of poorly absorbed drugs. Advanced drug delivery reviews. 2012; 64(6):480-95.
33. Tian F, Zeitler JA, Strachan CJ, Saville DJ, Gordon KC, Rades T, Characterizing the conversion kinetics of carbamazepine polymorphs to the dihydrate in aqueous suspension using Raman spectroscopy, Journal of pharmaceutical and biomedical analysis, 2006; 40(2):271- 280.
34. Ikeda Y, Ishihara Y, Moriwaki T, Kato E, Terada K. A novel analytical method for pharmaceutical polymorphs by terahertz spectroscopy and the optimization of crystal form at the discovery stage, Chemical and Pharmaceutical Bulletin, 2010; 58(1):76-81.
35. Otsuka M, Nishizawa JI, Shibata J, Ito M, Quantitative evaluation of mefenamic acid polymorphs by terahertz-chemometrics, Journal of Pharmaceutical Sciences, 2010; 99(9):4048-4053.
36. Bond L, Allen S, Davies MC, Roberts CJ, Shivji AP, Tendler SJ, Williams PM, Zhang J, Differential scanning calorimetry and scanning thermal microscopy analysis of pharmaceutical materials, International journal of pharmaceutics, 2002; 243(1-2):71-82.
37. Van Eerdenbrugh B, Froyen L, Martens JA, Blaton N, Augustijns P, Brewster M, Van den Mooter G, Characterization of physico-chemical properties and pharmaceutical performance of sucrose co-freeze–dried solid nanoparticulate powders of the anti-HIV agent loviride prepared by media milling. International journal of pharmaceutics, 2007; 338(1-2):198-206.
38. Gao Y, Li Z, Sun M, Li H, Guo C, Cui J, Li A, Cao F, Xi Y, Lou H, Zhai G, Preparation, characterization, pharmacokinetics, and tissue distribution of curcumin nanosuspension with TPGS as stabilizer, Drug development and industrial pharmacy, 2010; 36(10):1225-34.
39. Shi J, Steric Stabilization, Literature Review, Center for Industrial Sensors and Measurements, Materials Science Engineering Department, Inorganic Materials Science Group, The Ohio State University, 2002.
40. Deshiikan SR, Papadopoulos KD, Modified Booth equation for the calculation of zeta potential.
41. Liang Y, Binner J, Effect of triblock copolymer non-ionic surfactants on the rheology of 3 mol% yttria stabilised zirconia nanosuspensions, Ceramics international, 2008; 34(2):293-7.
42. Chaurasia T, Singh D, Nimisha DS, A review on nanosuspensions promising drug delivery strategy, Current Pharma Research, 2012; 3(1):764-76.
43. Kocbek P, Baumgartner S, Kristl J, Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugs, International journal of pharmaceutics, 2006; 312(1-2):179-86.
44. Muller RH, Keck CM, Challenges and solutions for the delivery of biotech drugs, a review of drug nanocrystal technology and lipid nanoparticles, Journal of biotechnology, 2004; 113(1-3):151-70.
45. Rabinow BE, Nanosuspensions in drug delivery, Nature Reviews Drug Discovery, 2004; 3(9):785.
46. Zhao YX, Hua HY, Chang M, Liu WJ, Zhao Y, Liu HM, Preparation and cytotoxic activity of hydroxycamptothecin nanosuspensions, International journal of pharmaceutics, 2010; 392(1-2):64-71.
47. Lamb H, Hydrodynamics, Cambridge university press ; 1993.
48. Kayser O, Lemke A, Hernandez-Trejo N, The impact of nanobiotechnology on the development of new drug delivery systems, Current pharmaceutical biotechnology, 2005; 6(1):3-5.
49. Merisko Liversidge E, Liversidge GG, Cooper ER, Nanosizing a formulation approach for poorly-water-soluble compounds, European Journal of Pharmaceutical Sciences, 2003; 18(2):113-20.
50. Jeong SC, Kim DS, Jin SG, Youn YS, Oh KT, Li DX, Yong CS, Oh Kim J, Kim KS, Choi HG, Development of a novel celecoxib-loaded nanosuspension using a wet media milling process, Pharmazie, 2018;73(9):498-502.
51. Wang Z, Li Z, Zhang D, Miao L, Huang G, Development of etoposide-loaded bovine serum albumin nanosuspensions for parenteral delivery, Drug Deliv, 2015; 22(1):79-85.
52. Tian X, Li H, Zhang D, Liu G, Jia L, Zheng D, Shen J, Shen Y, Zhang Q, Nanosuspension for parenteral delivery of a p-terphenyl derivative: preparation, characteristics and pharmacokinetic studies, Colloids and Surfaces B: Biointerfaces. 2013 ; 1(108):29-33.
53. Yin T, Cai H, Liu J, Cui B, Wang L, Yin L, Zhou J, Huo M. Biological evaluation of PEG modified nanosuspensions based on human serum albumin for tumor targeted delivery of paclitaxel. Eur J Pharm Sci, 2016; 15(83):79-87.
54. Hong J1, Sun Z1, Li Y1, Guo Y1, Liao Y1, Liu M2, Wang X1, Folate-modified Annonaceous acetogenins nanosuspensions and their improved antitumor efficacy, Int J Nanomedicine, 2017; 14(12):5053-5067.
55. Madni A1, Rahem MA2, Tahir N3, Sarfraz M2, Jabar A2, Rehman M2, Kashif PM2, Badshah SF2, Khan KU2, Santos HA4, Non-invasive strategies for targeting the posterior segment of eye, Int J Pharm, 2017; 530(1-2):326-345.
56. Garcia-Millan E, Quintáns-Carballo M, Otero-Espinar FJ, Improved release of triamcinolone acetonide from medicated soft contact lenses loaded with drug nanosuspensions, International Journal of Pharmaceutics, 2017; 525(1): 226-236.
57. Ambhore NP1, Dandagi PM2, Gadad AP2, Formulation and comparative evaluation of HPMC and water soluble chitosan-based sparfloxacin nanosuspension for ophthalmic delivery, Drug Deliv Transl Res, 2016; 6(1):48-56.
58. Hernandez-Trejo N, Kayser O, Steckel H, Müller RH. Characterization of nebulized buparvaquone nanosuspensions effect of nebulization technology, Journal of drug targeting, 2005; 13(8-9):499-507.
59. Rossi I, Sonvico F, McConville JT, Rossi F, Fröhlich E, Zellnitz S, Rossi A, Del Favero E, Bettini R, Buttini F, Nebulized coenzyme Q10 nanosuspensions: a versatile approach for pulmonary antioxidant therapy, European Journal of Pharmaceutical Sciences, 2018 ; 15(113):159-70.
60. Oktay AN, Karakucuk A, Ilbasmis-Tamer S, Celebi N, Dermal flurbiprofen nanosuspensions: Optimization with design of experiment approach and in vitro evaluation. European Journal of Pharmaceutical Sciences, 2018; 15(122):254-263.
61. Pireddu R, Sinico C, Ennas G, Schlich M, Valenti D, Murgia S, Marongiu F, Fadda AM, Lai F, The effect of diethylene glycol monoethyl ether on skin penetration ability of diclofenac acid nanosuspensions, Colloids Surf B Biointerfaces, 2018; 162:8-15.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).